Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States

NCT05266248 | Completed Phase 1

• 1 other identifier: PEP-2116
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Pilot study designed to characterize the plasma caffeine pharmacokinetic profile of encapsulated caffeine when consumed in the fasted and fed states.

Conditions

Pharmacokinetics

Keywords

caffeine; plasma; encapsulated; beverage

Outcome Measures

Primary Outcomes (4)

• Area under the concentration curve for plasma caffeine (AUC0-t)

  Plasma caffeine pharmacokinetics

  Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion

• Peak caffeine concentration (Cmax)

  Plasma caffeine pharmacokinetics

  Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion

• Time to maximal plasma caffeine concentration (Tmax)

  Plasma caffeine pharmacokinetics

  Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion

• Plasma caffeine concentration by time profile

  Plasma caffeine pharmacokinetics

  Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion

Secondary Outcomes (3)

• Vital sign measurement: Systolic and diastolic blood pressure

  Changes in systolic and diastolic blood pressure over 6.5 hours, from prior to blood sample collection at -30 minutes pre-dose to 2 and 6 hours after the first sip of beverage ingestion

• Vital sign measurement: Heart rate

  Changes in heart rate over 6.5 hours, from prior to blood sample collection at -30 minutes pre-dose to 2 and 6 hours after the first sip of beverage ingestion

• Occurrence of Adverse events

  From the first sip of beverage ingestion (Time 0) of the first dosing day, until the subject exits the study the evening of the second and last dosing day. The two dosing days are approximately 7 days apart.

Study Arms (2)

Fed state

EXPERIMENTAL

Standardized high fat breakfast before dosing

Other: 250 mg encapsulated caffeine

Fasted state

EXPERIMENTAL

Remain fasted for 4 hours post-dose

Other: 250 mg encapsulated caffeine

Interventions

250 mg encapsulated caffeine OTHER

Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage

Fasted state; Fed state

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult male and female volunteers aged 18 to 55 years.
• Have a BMI of 18 to 29.9 kg/m2 (inclusive)
• Are regular caffeine consumers (average 1 to 3 caffeine-containing beverages per day, not to exceed 400 mg/ per day)
• Willing to commit to 1 overnight stays (\~36 hrs)
• Able to comprehend and willing to sign an Informed Consent Form (ICF)
• Willing to avoid caffeine-containing products for ≥48 hrs prior to dosing and until the completion of each test visit
• Willing to avoid alcohol for ≥24 hrs prior to dosing
• Willing to fast 10 hrs prior to dosing
• Willing to stick to their usual dietary patterns and avoid grapefruit
• Willing to stick to their usual physical activity level throughout the study
• Willing to stick to their usual sleep pattern
• Willing and able to consume a high-fat, high-caloric breakfast
• No participation in any clinical trial within the past 30 days or 5 half lives and throughout this study, or any PEP protocol within the past 6 months.

You may not qualify if:

• Reported history or clinical manifestations of significant metabolic (including type 1 or type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders unless deemed clinically not significant by investigator
• Current or recent history (\<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
• Current clinically significant viral infection
• History of malignancy within the past 5 years, with the exception of cured basal cell or squamous cell carcinoma of the skin within 6 months
• Are pregnant or breastfeeding or planning to become pregnant
• Resting heart rate less than 45 bpm or greater than 100 bpm.
• History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure 150/90 mm Hg)
• History of significant surgery that may affect absorption of caffeine. Appendectomy and/or cholecystectomy will be allowed.
• Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis).
• Extreme dietary habits, including but not limited to intentional consumption of a high fiber diet, gluten-free, low-carb, vegan, ketogenic.
• History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations.
• More than one tobacco-containing or nicotine-containing product occasions per month on average, or use of such products within 48 hours prior to dosing of each study period
• Use of any prescription or nonprescription drugs (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) is prohibited within 7 days prior to the dose of study product, unless deemed acceptable by the Investigator.
• Use of any medication known to have an interaction with caffeine including oral contraceptives (e.g., medications metabolized via the CYP1A2 pathway). Contraceptives with localized effects (e.g., copper and hormonal IUDs, vaginal ring) are acceptable, methods with systemic effects (e.g., patch or subdermal implants/devices) are not.
• Use of any medication known to alter the pH of the gastrointestinal tract (e.g., proton-pump inhibitors, histamine H2-receptor antagonists (H2 blockers), antacids, etc.).

Sponsors & Collaborators

• PepsiCo Global R&D: lead

Study Sites (1)

GCP Research

St. Petersburg, Florida, 33705, United States

Location

Study Officials

• Lawrence Galitz, MD

  GCP, Global Clinical Professionals

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 26, 2022
• First Posted: March 4, 2022
• Study Start: January 25, 2022
• Primary Completion: February 3, 2022
• Study Completion: February 3, 2022
• Last Updated: March 24, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)